Current diabetes and metabolic health news selected for patient safety, public usefulness, novelty, and evidence strength.News posts summarize source material in plain language and include practical takeaways. They are not individualized medical advice and should not replace clinician guidance.
FDA granted accelerated approval for Tzield in children ages 8 to 17 recently diagnosed with Stage 3 type 1 diabetes. Here is what families should know.
Phase 3 retatrutide data in recent-onset type 2 diabetes showed A1C lowering and weight loss. The drug remains investigational and is not FDA-approved.
A new FLOW analysis reports that semaglutide kidney and all-cause death benefits were consistent across cardiovascular-risk groups in adults with type 2 diabetes and chronic kidney disease.
